Global protein differential expression profiling of cerebrospinal fluid samples pooled from chinese sporadic CJD and non-CJD patients

Molecular Neurobiology

Volumn 49, Issue 1, 2014, Pages 290-302

  Zhang, Jian Zhong ^a   Chen, Cao ^a   Xiao, Di ^a   Zhou, Wei ^a   Shi, Qi ^a   Zhang, Hui Fang ^a   Zhang, Jin ^a   Tian, Chan ^a   Dong, Xiao Ping ^a,b  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b INSTITUTE OF MICROBIOLOGY   (China)

Author keywords

Creutzfeldt Jakob disease; CSF; Differential protein expression; RP RP UPLC MS MS; TMT labeling

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; PHOSPHOGLYCERATE MUTASE;

ADOLESCENT; ADULT; AGED; CEREBROSPINAL FLUID; CHINESE; COMPARATIVE STUDY; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DOWN REGULATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MIDDLE AGED; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SPORADIC CREUTZFELDT JAKOB DISEASE; UPREGULATION; VERY ELDERLY; WESTERN BLOTTING; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; CREUTZFELDT-JAKOB SYNDROME; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 84894317568     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-013-8519-2     Document Type: Review

References (58)

1. Prusiner SB, Scott MR, DeArmond SJ, Cohen FE (1998) Prion protein biology. Cell 93(3):337-348
2. Budka H, Aguzzi A, Brown P, Brucher JM, Bugiani O, Gullotta F, Haltia M, Hauw JJ, Ironside JW, Jellinger K et al (1995) Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Brain Pathol 5(4):459-466
3. Gary H, Kimbra K, Clarence JG, Kelvin HL, Michael GH (1996) The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med 335:7
4. Weber T, Otto M, Bodemer M, Zerr I (1997) Diagnosis of Creutzfeldt-Jakob disease and related human spongiform encephalopathies. Biomed Pharmacother 51(9):381-387
5. WHO (2003) WHO manual for surveillance of human transmissible spongiform encephalopathies including variant Creutzfeldt-Jakob disease. WHO Communicable Disease Surveillance and Response
6. Zerr I, Kallenberg K, Summers DM, Romero C, Taratuto A, Heinemann U, Breithaupt M, Varges D, Meissner B, Ladogana A, Schuur M, Haik S, Collins SJ, Jansen GH, Stokin GB, Pimentel J, Hewer E, Collie D, Smith P, Roberts H, Brandel JP, van Duijn C, Pocchiari M, Begue C, Cras P, Will RG, Sanchez-Juan P (2009) Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain 231:10
7. Van Everbroeck B, Boons J, Cras P (2005) Cerebrospinal fluid biomarkers in Creutzfeldt-Jakob disease. Clin Neurol Neurosurg 107(5):355-360
8. Pennington C, Chohan G, Mackenzie J, Andrews M, Will R, Knight R, Green A (2009) The role of cerebrospinal fluid proteins as early diagnostic markers for sporadic Creutzfeldt-Jakob disease. Neurosci Lett 455(1):56-59
9. Otto M, Wiltfang J, Cepek L, Neumann M, Mollenhauer B, Steinacker P, Ciesielczyk B, Schulz-Schaeffer W, Kretzschmar HA, Poser S (2002) Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 58(2):192-197
10. Jesse S, Steinacker P, Cepek L, von Arnim CA, Tumani H, Lehnert S, Kretzschmar HA, Baier M, Otto M (2009) Glial fibrillary acidic protein and protein S-100B: different concentration pattern of glial proteins in cerebrospinal fluid of patients with Alzheimer's disease and Creutzfeldt-Jakob disease. J Alzheimers Dis 17(3):541-551
11. Chen C, Shi Q, Zhang BY, Wang GR, Zhou W, Gao C, Tian C, Mei GY, Han YL, Han J, Dong XP (2010) The prepared tau exon-specific antibodies revealed distinct profiles of tau in CSF of the patients with Creutzfeldt-Jakob disease. PLoS One 5(7):e11886
12. Guntert A, Campbell J, Saleem M, O'Brien DP, Thompson AJ, Byers HL, Ward MA, Lovestone S (2010) Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease. J Alzheimers Dis 21(2):585-596
13. Zhang K, Schrag M, Crofton A, Trivedi R, Vinters H, Kirsch W (2012) Targeted proteomics for quantification of histone acetylation in Alzheimer's disease. Proteomics 12(8):1261-1268
14. Thompson A, Schafer J, Kuhn K, Kienle S, Schwarz J, Schmidt G, Neumann T, Johnstone R, Mohammed AK, Hamon C (2003) Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. Anal Chem 75(8):1895-1904
15. Dayon L, Hainard A, Licker V, Turck N, Kuhn K, Hochstrasser DF, Burkhard PR, Sanchez JC (2008) Relative quantification of proteins in human cerebrospinal fluids by MS/MS using 6-plex isobaric tags. Anal Chem 80(8):2921-2931
16. Li Z, Adams RM, Chourey K, Hurst GB, Hettich RL, Pan C (2012) Systematic comparison of label-free, metabolic labeling, and isobaric chemical labeling for quantitative proteomics on LTQ Orbitrap Velos. J Proteome Res 11(3):1582-1590
17. Chen C, Xiao D, Zhou W, Zhang YC, Shi Q, Tian C, Zhang J, Zhou CX, Zhang JZ, Dong XP (2012) Comparative peptidome analyses of the profiles of the peptides ranging from 1-10 KD in CSF samples pooled from probable sporadic CJD and non-CJD patients. Prion 6(1):46-51
18. Gilar M, Olivova P, Daly AE, Gebler JC (2005) Orthogonality of separation in two-dimensional liquid chromatography. Anal Chem 77(19):6426-6434
19. Gilar M, Olivova P, Daly AE, Gebler JC (2005) Two-dimensional separation of peptides using RP-RP-HPLC system with different pH in first and second separation dimensions. J Sep Sci 28(14):1694-1703
20. Keller A, Nesvizhskii AI, Kolker E, Aebersold R (2002) Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 74(20):5383-5392
21. Huang da W, Sherman BT, Tan Q, Kir J, Liu D, Bryant D, Guo Y, Stephens R, Baseler MW, Lane HC, Lempicki RA (2007) DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res 35(Web Server issue):W169-W175
22. da Huang W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4(1):44-57
23. Qualtieri A, Urso E, Le Pera M, Sprovieri T, Bossio S, Gambardella A, Quattrone A (2010) Proteomic profiling of cerebrospinal fluid in Creutzfeldt-Jakob disease. Expert Rev Proteomics 7(6):907-917
24. Salmona M, Capobianco R, Colombo L, De Luigi A, Rossi G, Mangieri M, Giaccone G, Quaglio E, Chiesa R, Donati MB, Tagliavini F, Forloni G (2005) Role of plasminogen in propagation of scrapie. J Virol 79(17):11225-11230
25. Mays CE, Ryou C (2010) Plasminogen stimulates propagation of protease-resistant prion protein in vitro. FASEB J 24(12):5102-5112
26. Piubelli C, Fiorini M, Zanusso G, Milli A, Fasoli E, Monaco S, Righetti PG (2006) Searching for markers of Creutzfeldt-Jakob disease in cerebrospinal fluid by two-dimensional mapping. Proteomics 6(Suppl 1):S256-S261
27. Singh A, Beveridge AJ, Singh N (2011) Decreased CSF transferrin in sCJD: a potential pre-mortem diagnostic test for prion disorders. PLoS One 6(3):e16804
28. Miele G, Seeger H, Marino D, Eberhard R, Heikenwalder M, Stoeck K, Basagni M, Knight R, Green A, Chianini F, Wuthrich RP, Hock C, Zerr I, Aguzzi A (2008) Urinary alpha1-antichymotrypsin: a biomarker of prion infection. PLoS One 3(12):e3870
29. Quinn JF (2013) Biomarkers for Alzheimer's disease: showing the way or leading us astray? J Alzheimers Dis 33(Suppl 1):S371-S376
30. Keeney JT, Swomley AM, Forster S, Harris JL, Sultana R, Butterfield DA (2013) Apolipoprotein A-I: insights from redox proteomics for its role in neurodegeneration. Proteomics Clin Appl 7(1-2):109-122
31. Zerr I, Bodemer M, Racker S, Grosche S, Poser S, Kretzschmar HA, Weber T (1995) Cerebrospinal fluid concentration of neuron-specific enolase in diagnosis of Creutzfeldt-Jakob disease. Lancet 345(8965):1609-1610
32. Kohira I, Tsuji T, Ishizu H, Takao Y, Wake A, Abe K, Kuroda S (2000) Elevation of neuron-specific enolase in serum and cerebrospinal fluid of early stage Creutzfeldt-Jakob disease. Acta Neurol Scand 102(6):385-387
33. Brechlin P, Jahn O, Steinacker P, Cepek L, Kratzin H, Lehnert S, Jesse S, Mollenhauer B, Kretzschmar HA, Wiltfang J, Otto M (2008) Cerebrospinal fluid-optimized two-dimensional difference gel electrophoresis (2-D DIGE) facilitates the differential diagnosis of Creutzfeldt-Jakob disease. Proteomics 8(20):4357-4366
34. Gawinecka J, Dieks J, Asif AR, Carimalo J, Heinemann U, Streich JH, Dihazi H, Schulz-Schaeffer W, Zerr I (2010) Codon 129 polymorphism specific cerebrospinal fluid proteome pattern in sporadic Creutzfeldt-Jakob disease and the implication of glycolytic enzymes in prion-induced pathology. J Proteome Res 9(11):5646-5657
35. Ulloa L, Montejo de Garcini E, Gomez-Ramos P, Moran MA, Avila J (1994) Microtubule-associated protein MAP1B showing a fetal phosphorylation pattern is present in sites of neurofibrillary degeneration in brains of Alzheimer's disease patients. Brain Res Mol Brain Res 26(1-2):113-122
36. Gonzalez-Billault C, Jimenez-Mateos EM, Caceres A, Diaz-Nido J, Wandosell F, Avila J (2004) Microtubule-associated protein 1B function during normal development, regeneration, and pathological conditions in the nervous system. J Neurobiol 58(1):48-59
37. Xu G, Stevens SM Jr, Moore BD, McClung S, Borchelt DR (2013) Cytosolic proteins lose solubility as amyloid deposits in a transgenic mouse model of Alzheimer-amyloidosis. Hum Mol Genet 22(14):2765-74
38. Zerr I, Bodemer M, Kaboth U, Kretzschmar H, Oellerich M, Armstrong VW (2004) Plasminogen activities and concentrations in patients with sporadic Creutzfeldt-Jakob disease. Neurosci Lett 371(2-3):163-166
39. Choe LH, Green A, Knight RS, Thompson EJ, Lee KH (2002) Apolipoprotein E and other cerebrospinal fluid proteins differentiate ante mortem variant Creutzfeldt-Jakob disease from ante mortem sporadic Creutzfeldt-Jakob disease. Electrophoresis 23(14):2242-2246
40. Fischer MB, Roeckl C, Parizek P, Schwarz HP, Aguzzi A (2000) Binding of disease-associated prion protein to plasminogen. Nature 408(6811):479-483
41. Maissen M, Roeckl C, Glatzel M, Goldmann W, Aguzzi A (2001) Plasminogen binds to disease-associated prion protein of multiple species. Lancet 357(9273):2026-2028
42. Ishii T, Haga S, Yagishita S, Tateishi J (1984) The presence of complements in amyloid plaques of Creutzfeldt-Jakob disease and Gerstmann-Straussler-Scheinker disease. Appl Pathol 2(6):370-379
43. Klein MA, Kaeser PS, Schwarz P, Weyd H, Xenarios I, Zinkernagel RM, Carroll MC, Verbeek JS, Botto M, Walport MJ, Molina H, Kalinke U, Acha-Orbea H, Aguzzi A (2001) Complement facilitates early prion pathogenesis. Nat Med 7(4):488-492
44. Mabbott NA, Bruce ME, Botto M, Walport MJ, Pepys MB (2001) Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie. Nat Med 7(4):485-487
45. Erlich P, Dumestre-Perard C, Ling WL, Lemaire-Vieille C, Schoehn G, Arlaud GJ, Thielens NM, Gagnon J, Cesbron JY (2010) Complement protein C1q forms a complex with cytotoxic prion protein oligomers. J Biol Chem 285(25):19267-19276
46. Speth C, Dierich MP, Gasque P (2002) Neuroinvasion by pathogens: a key role of the complement system. Mol Immunol 38(9):669-679
47. Finehout EJ, Franck Z, Lee KH (2005) Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease. Dis Markers 21(2):93-101
48. Gasque P, Dean YD, McGreal EP, VanBeek J, Morgan BP (2000) Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology 49(1-2):171-186
49. Tuppo EE, Arias HR (2005) The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol 37(2):289-305
50. Yamada T, McGeer PL, McGeer EG (1992) Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins. Acta Neuropathol 84(1):100-104
51. McGeer PL, McGeer EG (2004) Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 10(Suppl 1):S3-S7
52. Sellebjerg F, Jaliashvili I, Christiansen M, Garred P (1998) Intrathecal activation of the complement system and disability in multiple sclerosis. J Neurol Sci 157(2):168-174
53. Kornek B, Lassmann H (2003) Neuropathology of multiple sclerosis - new concepts. Brain Res Bull 61(3):321-326
54. Tian C, Liu D, Chen C, Xu Y, Gong HS, Shi Q, Zhang BY, Han J, Dong XP (2013) Global transcriptional profiling of the postmortem brain of a patient with G114V genetic Creutzfeldt-Jakob disease. Int J Mol Med 31(3):676-688
55. Tian C, Liu D, Sun QL, Chen C, Xu Y, Wang H, Xiang W, Kretzschmar HA, Li W, Shi Q, Gao C, Zhang J, Zhang BY, Han J, Dong XP (2013) Comparative analysis of gene expression profiles between cortex and thalamus in Chinese fatal familial insomnia patients. Mol Neurobiol. doi: 10.1007/s12035-013-8426-6
56. Kropp S, Zerr I, Schulz-Schaeffer WJ, Riedemann C, Bodemer M, Laske C, Kretzschmar HA, Poser S (1999) Increase of neuron-specific enolase in patients with Creutzfeldt-Jakob disease. Neurosci Lett 261(1-2):124-126
57. Fountoulakis M, Cairns N, Lubec G (1999) Increased levels of 14-3-3 gamma and epsilon proteins in brain of patients with Alzheimer's disease and Down syndrome. J Neural Transm Suppl 57:323-335
58. Singh A, Isaac AO, Luo X, Mohan ML, Cohen ML, Chen F, Kong Q, Bartz J, Singh N (2009) Abnormal brain iron homeostasis in human and animal prion disorders. PLoS Pathog 5(3):e1000336